<DOC>
	<DOCNO>NCT00672477</DOCNO>
	<brief_summary>This study evaluate safety efficacy methylnaltrexone administer subcutaneous injection subject opioid-induced constipation advance illness . The hypothesis methylnaltrexone safe effective relieve opioid-induced constipation subject .</brief_summary>
	<brief_title>Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>Is adult 18 year age older Has diagnosis advance illness ( ie , terminal illness incurable cancer endstage disease ) Has life expectancy least 1 month . Is receive opioids regular schedule ( asneeded rescue dos ) control pain discomfort least 2 week first dose study drug . Has constipation cause opioid medication . Has know suspect allergy methylnaltrexone similar compound ( e.g . naltrexone naloxone ) . Has know suspect mechanical gastrointestinal obstruction . Has potential nonopioid cause bowel dysfunction might major contributor constipation . Has clinically important abnormality determine investigator may interfere participation compliance study . Receiving opioid antagonist partial antagonist product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>opioid-induced constipation</keyword>
</DOC>